Register
Login:
Share:
Email Facebook Twitter

Be a contrarian investor says Ranjeet Singh Watch here

Be a contrarian investor says Ranjeet Singh


Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 52.25Bid: 51.75Ask: 52.75Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 1.00Spread as %: 1.93%Open: 53.00High: 53.25Low: 52.00Yesterday’s Close: 52.25

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
52.25

Share Price SpacerBid
51.75

Share Price SpacerAsk
52.75

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
158,854

Share Price SpacerOpen
53.00

Share Price SpacerHigh
53.25

Share Price SpacerLow
52.00

Share Price SpacerClose
52.25

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 132.52m £68.91m 5,000

52 Week High 69.00 52 Week High Date 17-FEB-2017
52 Week Low 25.25 52 Week Low Date 25-APR-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
34 82,105 76,749 -11.818 -4.40 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

21-Apr-17
16:54:05
52.50
8,771
Buy* 
51.75
52.75
4,605
Trade Type:
Ordinary
Bargain conditions apply

21-Apr-17
16:16:05
52.4375
10,000
Buy* 
51.50
52.75
5,244
Trade Type:
Ordinary

21-Apr-17
16:06:06
52.4375
1,000
Buy* 
51.50
52.75
524.38
Trade Type:
Ordinary




View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Sat 09:03leasRE: 201652.25No Opinion
Howdy Partner. Last year it was the first week in May so it will be interesting to see if there is any rise in volume going into the bank Hols. sp drifting without news atm but no concerns. Last month we had quite a few news releases and this month zero (so far)
Fri 13:50NagyPipeline52.00No Opinion
They should be presenting next week on the new pipeline.
Fri 12:52Mcowboy201652.00No Opinion
End of year results should be announced soon, so we should get a further update on the Lupuzor phase 3 trial and any developments regarding the company's other compounds in the near future.
Wed 21:15leasA reminder ....55.625No Opinion
Wed 21:15leasboom55.625No Opinion
read your post over on the motif bb. I think the same applies here. P140 is not about trying to compete with alternative treatments, it's about replacing them. Many more sufferers that will be able to take undergo treatment, some that have already had transplants caused by this dreadful disease. Some investors are trying to make comparisons with benylsta and market share. Lots more patients potentially having access to treatment if approved.
Tue 23:01hunkymonkeyRE: good start55.75No Opinion
Up 10% then flat. Quite strange, similar to motif

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.